Urodynamics/Lower Urinary Tract Dysfunction/ Female Pelvic Medicine: Non-neurogenic Voiding Dysfunction II Moderated Poster 63 Monday, September 13, 2021 10:30 AM-11:45 AM MP63-01 PAIN CATASTROPHIZING IS ASSOCIATED WITH WORSE PAIN OUTCOMES FOR SPECIALIZED PELVIC PT Shashank S. Pandya*, Daniel Alaiev, Lake Success, NY; Danielle Wang, Sacremento, CA; Katelyn Kunkle, Huntington, NY,; Lindsey Nyman, Jennifer Fariello-Moldwin, Lake Success, NY; Stephanie Goldstein, Huntington, NY; Robert M. Moldwin, Lake Success, NY INTRODUCTION AND OBJECTIVE: Pain catastrophizing consists of exaggerated ruminating negative thoughts and emotions brought on by an actual, perceived, or an anticipated painful stimulus. Pain catastrophizing leads to less improvement over time. We sought to predict the relationship between pain catastrophizing and the outcomes of specialized pelvic fl oor physical therapy (PT). METHODS: Data was collected retrospectively between 2019-2020 from 39 patients (35 females and 4 males between the ages 18-72) diagnosed with UCPPS with pelvic floor myalgia who underwent 6 weeks of 1-2 sessions/ week of specialized pelvic PT. All patients filled out the short version of the Pain Catastrophizing Scale (PCS; 0-24) and the Genitourinary Pain Index (GUPI; 0-45) before and after 6 six weeks of PT. Sets of Bayesian binomial regression models were generated to predict changes in pain scores using the full GUPI, GUPI Pain Subscale (0-23), Visual Analog Score (VAS; 0-10), and PCS split into terciles, quartiles, or maximum/minimum. A standard null model was fit as a benchmark against other models. PSIS-LOO cross-validation with pseudo-BMA weighting was used to select the best performing model. RESULTS: The best performing model predicted a signi ficant clinical change in VAS after six weeks of PT for minimum/non-pain catastrophizers (NC; 0 PCS) and maximum/extreme pain catastrophizers (EC; 24 PCS). Table 1 shows the predictions for the change in VAS from baseline ( DVAS[Week 6- initial VAS) after six weeks of PT. For example, at a baseline VAS of 6 and an initial PCS of 0 (NC), 97.1 % (posterior probability) of the time, the model predicts a median improvement of 3 points after with 95% (Bayesian credible interval) of the predictions falling between an improvement of 1 to 6 points. With the same baseline VAS of 6, if the initial PCS was 24 (EC), 97.1% of the time, the model predicts a median improvement of 0 with 95% of the predictions falling between an improvement of 2 points to a worsening of 3 points. CONCLUSIONS: NC's were predicted to have improved VAS scores than EC's after 6 weeks of PT. Unlike the Pain Subscale or GUPI, which are composite scores, VAS is better at predicting change over time (test-retest reli- ability). This has implications for future studies' choice of instrument for tracking pain over time. A signi ficant limitation of this model is the small sample size. Source of Funding: N/A MP63-02 NEW OR WORSENING OVERACTIVE BLADDER SYMPTOMS AFTER RECOVERY FROM COVID-19 Wen Chen*, Dragana Komnenov, Ryan Timar, Melissa Wills, Sorabh Dhar, Nivedita Dhar, Detroit, MI INTRODUCTION AND OBJECTIVE: Since the emergence of the coronavirus disease (COVID-19) in December 2019, it has become evident that additional to the respiratory impairment, many other organ systems are targeted by the disease-causing SARS-CoV2 virus. Due to the paucity of data regarding genitourinary symptoms in COVID-19, we set out to investigate the disease manifestation(s) in bladder function. We identified recovered COVID-19 patients presenting with new or worsening overactive bladder symptoms, known as COVID-19 Associated Cystitis (CAC). METHODS: We used AUA Urology Care Foundation Over- active Bladder (OAB) Assessment Tool to screen COVID-19 recovered patients at our urban-located institution from 5/22/2020 to 12/31/2020. Primary outcomes include patient responses to 5 symptom and 4 quality-of-life questions (QOL). We reported median symptom scores, as well as quality-of-life scores, based on new or worsening urinary symptoms stratified by sex. RESULTS: We identified 350 patients with de novo or wors- ening OAB symptoms. In patients with new onset OAB symptoms, the median symptom score was 18. Patients with worsening OAB symp- toms had a median pre-COVID-19 symptom score of 8 which was exacerbated post-COVID-19 as indicated by the median symptom score of 19. The median total QOL score for both men and women was 19. In patients with worsening OAB, median pre-COVID-19 QOL score was 9 compared to median post-COVID-19 QOL score of 20. Median age was 64.5 (range 47-82). Median length of stay was 10 days (range 5-30). CONCLUSIONS: Here we report survey-based results of patients suffering from new or worsening OAB symptoms after recovery from COVID-19 which necessitated hospitalization. The total median symptom score for patients with de novo OAB was 18 and QOL score was19, irrespective of sex, indicating moderate to severe OAB. Exacerbation of symptoms post-COVID-19 in patients with existing OAB was evident by increases in symptom severity scores and deteriorating QOL. At present, the pathophysiological mechanisms of de novo or worsening OAB symptoms after recovery from COVID-19 are unknown. Vol. 206, No. 3S, Supplement, Monday, September 13, 2021 THE JOURNAL OF UROLOGY Ò e1101 Copyright © 2021 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.